ArticleJournal of ovarian research2026
The prognostic value of the Oocyte Maturation Index (OMI) on pregnancy outcomes in POSEIDON group 3 and 4 patients: a retrospective cohort study.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: The prognostic value of the Oocyte Maturation Index (OMI) on pregnancy outcomes in POSEIDON group 3 and 4 patients: a retrospective cohort study.Journal of ovarian research · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study
methodsA total of 662 patients treated at the Assisted Reproductive Techniques Unit of Mersin University Faculty of Medicine between 2016 and 2024 (Group 3: n=245; Group 4: n=417) were retrospectively analyzed. Patients were divided into three subgroups based on OMI values: ≤50%, 51-75%, and >75%.
resultsIn both POSEIDON groups, the numbers of aspirated follicles, retrieved oocytes, MII oocytes, and high-quality day-3 embryos showed significant differences between OMI groups (p<0.001). In POSEIDON Group 3, patients with an OMI of 51-75% achieved the highest rates of biobiochemical pregnancy (43.9%), clinical pregnancy (42.1%), and live birth (35.1%), while these rates were lowest in the group with an OMI of ≤50% (10.9%, 10.9%, and 5.5%, respectively; p=0.001). In POSEIDON Group 4, while OMI significantly influenced chemical (p=0.005) and clinical pregnancy (p=0.014) rates, it did not result in a statistically significant difference in live birth rates (p=0.056).
conclusionOMI is a clinically significant prognostic parameter, particularly for younger patients in the POSEIDON Group 3. In older patients (Group 4), however, age-related oocyte proglems my controbite the decisive effect of OMI on live birth. Incorporating OMI into routine clinical evaluations may contribute to personalized treatment planning and patient counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.